Skip to main content
. 2018 Aug 6;14(8):e1007557. doi: 10.1371/journal.pgen.1007557

Fig 5. Loss of Baldspot reduces IRE1 RIDD activity.

Fig 5

(A) S2 Cells treated with DsRNA targeted against Baldspot had near complete reduction in Baldspot transcript levels (7.8%) as compared to control cells treated with DsRNA against EGFP. (B) DTT treatment increased Xbp1 splicing in control cells (2.96-fold increase), while splicing was reduced in cells treated with DsRNA against Baldspot (2.12-fold increase). (C) DTT treatment increased phosphorylation of eif2α in control cells, but not in cells treated with DsRNA against Baldspot. (D) Hydr2 expression is significantly reduced in control cells treated with DTT (0.71 ± 0.07), but not in cells treated with Baldspot DsRNA (0.91 ± 0.16). Sparc expression is significantly reduced in both control and Baldspot knockdown cells treated with DTT (0.71 ± 0.06 in controls and 0.74 ± 0.09 in Baldspot knockdown). Actin5c transcript levels were unaffected by DTT treatment (1.19 ± 0.06 in controls and 1.16 ± 0.45 in Baldspot knockdown). The dotted line indicates transcript levels in cells treated with DMSO. * P < 0.05, ** P < 0.005, **** P < 0.0001, # P < 0.05.